Pressemitteilungen

Martinsried/Munich July, 10 2009. MediGene AG (Frankfurt: MDG, Prime Standard, TecDAX) today announces that its Marketing Authorisation Application for the medicinal product Veregen® (formerly Polyphenon E® Ointment) for the treatment of genital warts has been assessed positively by the national regulatory authorities of Germany, Austria, and Spain. This binding decision guarantees that national Marketing Authorisations in these countries will be formally granted by the authorities within the next few months. The Marketing Authorisation of Veregen® in Germany, the Reference Member State in this Decentralized Procedure, shall provide the basis for additional Marketing Authorisations in other European countries via the Mutual Recognition Procedure.

This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the statements made herein. MediGene is not bound to update any of these forward-looking statements.

- Ende –

Die MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG, TecDAX) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company to have drugs on the market, which are being distributed by partner companies. MediGene has several drug candidates in clinical development, including EndoTAG™-1, which could offer substantial sales returns. In addition, the company has numerous projects in research and pre-clinical development and possesses innovative platform technologies. MediGene focuses on the research and development of novel drugs for the treaTMent of cancer and autoimmune diseases.